Cargando…

Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19

INTRODUCTION: The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Tunjungputri, Rahajeng N., Tetrasiwi, Erpryta Nurdia, Veronica, Merlinda, Pandelaki, Jacub, Ibrahim, Fera, Nelwan, Erni Juwita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570879/
https://www.ncbi.nlm.nih.gov/pubmed/34745267
http://dx.doi.org/10.1155/2021/9673453
_version_ 1784594909583376384
author Tunjungputri, Rahajeng N.
Tetrasiwi, Erpryta Nurdia
Veronica, Merlinda
Pandelaki, Jacub
Ibrahim, Fera
Nelwan, Erni Juwita
author_facet Tunjungputri, Rahajeng N.
Tetrasiwi, Erpryta Nurdia
Veronica, Merlinda
Pandelaki, Jacub
Ibrahim, Fera
Nelwan, Erni Juwita
author_sort Tunjungputri, Rahajeng N.
collection PubMed
description INTRODUCTION: The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-associated disease enhancement (VADE) is the modified presentation of infections in individuals after having received a prior vaccination. Currently, little is known about the potential of vaccine-associated disease enhancement (VADE) following COVID-19 immunization. Case Illustration. We herewith report two patients admitted with confirmed COVID-19 pneumonia with a history of CoronaVac vaccination. The first patient with a relatively milder course of the disease had received two doses of CoronaVac, whereas the second patient with a more progressive course of the disease received only one dose before developing symptoms and being admitted to the hospital. Our observations suggest that vaccination could act in boosting the inflammatory process and reveal the previously asymptomatic COVID-19 illness. Theoretically, vaccines could induce VADE, where only suboptimal, nonprotective titers of neutralizing antibodies were produced or proinflammatory T-helper type 2 response was induced. Secondly, enhanced respiratory disease (ERD) could manifest, where pulmonary symptoms are more severe due to peribronchial monocytic and eosinophilic infiltration. Understanding VADE is important for the decision-making by the public, clinicians, and policymakers and is warranted for successful vaccination uptake. CONCLUSION: We report two cases of patients developing COVID-19 shortly after CoronaVac vaccination in which VADE is likely. We recommend that current vaccination strategies consider the measurement of neutralizing antibody titer as a guide in ensuring the safest strategy for mass immunization. Studies are needed to investigate the true incidence of VADE on vaccinated individuals as well as on how to differentiate between VADE and severe manifestations of COVID-19 that are unrelated to vaccination.
format Online
Article
Text
id pubmed-8570879
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-85708792021-11-06 Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19 Tunjungputri, Rahajeng N. Tetrasiwi, Erpryta Nurdia Veronica, Merlinda Pandelaki, Jacub Ibrahim, Fera Nelwan, Erni Juwita Case Rep Med Case Report INTRODUCTION: The COVID-19 pandemic has entered a new phase with the roll-out of several vaccines worldwide at an accelerated phase. The occurrence of a more severe presentation of COVID-19 after vaccination may affect policymakers' decision-making and vaccine uptake by the public. Vaccine-associated disease enhancement (VADE) is the modified presentation of infections in individuals after having received a prior vaccination. Currently, little is known about the potential of vaccine-associated disease enhancement (VADE) following COVID-19 immunization. Case Illustration. We herewith report two patients admitted with confirmed COVID-19 pneumonia with a history of CoronaVac vaccination. The first patient with a relatively milder course of the disease had received two doses of CoronaVac, whereas the second patient with a more progressive course of the disease received only one dose before developing symptoms and being admitted to the hospital. Our observations suggest that vaccination could act in boosting the inflammatory process and reveal the previously asymptomatic COVID-19 illness. Theoretically, vaccines could induce VADE, where only suboptimal, nonprotective titers of neutralizing antibodies were produced or proinflammatory T-helper type 2 response was induced. Secondly, enhanced respiratory disease (ERD) could manifest, where pulmonary symptoms are more severe due to peribronchial monocytic and eosinophilic infiltration. Understanding VADE is important for the decision-making by the public, clinicians, and policymakers and is warranted for successful vaccination uptake. CONCLUSION: We report two cases of patients developing COVID-19 shortly after CoronaVac vaccination in which VADE is likely. We recommend that current vaccination strategies consider the measurement of neutralizing antibody titer as a guide in ensuring the safest strategy for mass immunization. Studies are needed to investigate the true incidence of VADE on vaccinated individuals as well as on how to differentiate between VADE and severe manifestations of COVID-19 that are unrelated to vaccination. Hindawi 2021-10-29 /pmc/articles/PMC8570879/ /pubmed/34745267 http://dx.doi.org/10.1155/2021/9673453 Text en Copyright © 2021 Rahajeng N. Tunjungputri et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Tunjungputri, Rahajeng N.
Tetrasiwi, Erpryta Nurdia
Veronica, Merlinda
Pandelaki, Jacub
Ibrahim, Fera
Nelwan, Erni Juwita
Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19
title Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19
title_full Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19
title_fullStr Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19
title_full_unstemmed Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19
title_short Vaccine-Associated Disease Enhancement (VADE): Considerations in Postvaccination COVID-19
title_sort vaccine-associated disease enhancement (vade): considerations in postvaccination covid-19
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570879/
https://www.ncbi.nlm.nih.gov/pubmed/34745267
http://dx.doi.org/10.1155/2021/9673453
work_keys_str_mv AT tunjungputrirahajengn vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19
AT tetrasiwierprytanurdia vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19
AT veronicamerlinda vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19
AT pandelakijacub vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19
AT ibrahimfera vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19
AT nelwanernijuwita vaccineassociateddiseaseenhancementvadeconsiderationsinpostvaccinationcovid19